MSB 2.08% 94.0¢ mesoblast limited

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-383

  1. 1,609 Posts.
    lightbulb Created with Sketch. 1691
    I have an even harder time with scientifically-trained individuals dismissing something out of hand without appearing to have done their homework. Some of the most closed minds are educated ones that USED TO be open to questioning and exploring alternatives, but now just settle into their comfy little scope of knowledge and pooh-pooh anything that doesn't fit their world view and training.

    MSB is doing the science, and SI is a doctor himself. It's not hard to read the studies the company has done that totally support the science and demonstrated reproducible results, but apparently, it's too hard for oncologists and gastroenterologists, so they can just lob grenades into a bulletin board, safe in their house wallpapered with degrees. But if the medical establishment was more open to actually accepting results from rigourous trials--stem cell based or not--MSB would be much further down the track right now, and alot of patients that would benefit from these treatments would be better off by being able to get these treatments.

    The "First do no harm" oath works both ways - don't give patients treatments that don't work and cause harm--but also don't stubbornly and pigheadedly deny treatment to patients that DO work and DON'T cause harm (particularly not for egotistical reasons).
    Last edited by dplane: 24/04/20
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
94.0¢
Change
-0.020(2.08%)
Mkt cap ! $1.073B
Open High Low Value Volume
95.5¢ 97.0¢ 93.5¢ $1.424M 1.507M

Buyers (Bids)

No. Vol. Price($)
8 29390 93.5¢
 

Sellers (Offers)

Price($) Vol. No.
94.5¢ 14089 2
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.